Lewes, DE -- (SBWIRE) -- 09/19/2016 -- Myasthenia Gravis pipeline therapeutics constitutes close to 24 molecules. Out of which approximately 21 molecules are developed by Companies and remaining by the Universities/Institutes. Publisher's latest report Myasthenia Gravis – Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Myasthenia Gravis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

Myasthenia Gravis Myasthenia gravis is autoimmune neuromuscular disease characterized by weakness and rapid fatigue of any of the muscles under voluntary control. Symptoms include drooping of one or both eyelids, diplopia and difficulty swallowing, chewing and speaking. Treatment includes immunosuppressants, corticosteroids and surgery. The molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 4, 2, 11 and 2 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 2 molecules, respectively.

Furthermore, this report also reviews of key players involved in therapeutic development for Myasthenia Gravis and features dormant and discontinued projects. Driven by data built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

For more information Visit at: http://www.marketresearchreports.com/global-markets-direct/myasthenia-gravis-pipeline-review-h2-2016

Related Reports;

Influenza B Infections - Pipeline Review, H2 2016 - Visit at - http://www.marketresearchreports.com/global-markets-direct/influenza-b-infections-pipeline-review-h2-2016

Erectile Dysfunction - Pipeline Review, H2 2016 - Visit at - http://www.marketresearchreports.com/global-markets-direct/erectile-dysfunction-pipeline-review-h2-2016

Amyloidosis - Pipeline Review, H2 2016 - Visit at - http://www.marketresearchreports.com/global-markets-direct/amyloidosis-pipeline-review-h2-2016

Chemotherapy Induced Neutropenia - Pipeline Review, H2 2016 - Visit at - http://www.marketresearchreports.com/global-markets-direct/chemotherapy-induced-neutropenia-pipeline-review-h2-2016

About Market Research Reports, Inc.
Market Research Reports, Inc. is the world's leading source for market research reports and market data. We provide you with the latest market research reports on global markets, key industries, leading companies, new products and latest industry analysis & trends.

Yearly/Quarterly Report Subscription: http://www.marketresearchreports.com/subscriptions